Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
Authors
Keywords
Chimeric antigen receptor T-cells, Adoptive immunotherapy, Tumor microenvironment
Journal
Journal for ImmunoTherapy of Cancer
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-03-07
DOI
10.1186/s40425-017-0230-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
- (2017) Somala Mohammed et al. MOLECULAR THERAPY
- Chimeric antigen receptor T cell therapy: 25years in the making
- (2016) Saar Gill et al. BLOOD REVIEWS
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- The Emerging Hallmarks of Cancer Metabolism
- (2016) Natalya N. Pavlova et al. Cell Metabolism
- Innate immune signaling and regulation in cancer immunotherapy
- (2016) Leticia Corrales et al. CELL RESEARCH
- Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
- (2016) Eugene A Zhukovsky et al. CURRENT OPINION IN IMMUNOLOGY
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
- (2016) Gregory L. Beatty et al. PHARMACOLOGY & THERAPEUTICS
- Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
- (2016) K. Newick et al. Cancer Immunology Research
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
- (2015) A. Lo et al. CANCER RESEARCH
- A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
- (2015) Mythili Koneru et al. Journal of Translational Medicine
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
- (2015) Kevin J Curran et al. MOLECULAR THERAPY
- Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
- (2015) Ignazio Caruana et al. NATURE MEDICINE
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
- (2015) M. J. Frigault et al. Cancer Immunology Research
- IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo
- (2015) Mythili Koneru et al. OncoImmunology
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
- (2014) E. K. Moon et al. CLINICAL CANCER RESEARCH
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
- (2014) H J Pegram et al. LEUKEMIA
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment
- (2014) Duncan Howie et al. Frontiers in Immunology
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
- (2013) Eric Tran et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
- (2013) Petra C Schuberth et al. Journal of Translational Medicine
- Effect of Spatial and Temporal Cues on Athletic Pacing in Schoolchildren
- (2013) CAMILLA CHINNASAMY et al. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
- Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
- (2013) Sunitha Kakarla et al. MOLECULAR THERAPY
- Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
- (2013) L.-C. S. Wang et al. Cancer Immunology Research
- Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy
- (2012) L Zhang et al. GENE THERAPY
- Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
- (2012) Megan E. Prosser et al. MOLECULAR IMMUNOLOGY
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
- (2011) E. K. Moon et al. CLINICAL CANCER RESEARCH
- The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis
- (2011) Catherine E. Steding et al. IMMUNOLOGY
- Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
- (2010) S. P. Kerkar et al. CANCER RESEARCH
- Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses
- (2010) W. Peng et al. CLINICAL CANCER RESEARCH
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
- (2010) John A. Craddock et al. JOURNAL OF IMMUNOTHERAPY
- Lack of specific -retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation
- (2009) W. R. Burns et al. BLOOD
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started